TY - JOUR
T1 - Isoflurane postconditioning protects against reperfusion injury by preventing mitochondrial permeability transition by an endothelial nitric oxide synthase-dependent mechanism
AU - Ge, Zhi-Dong
AU - Pravdic, Danijel
AU - Bienengraeber, Martin
AU - Pratt, Phillip F.
AU - Auchampach, John A.
AU - Gross, Garrett J.
AU - Kersten, Judy R.
AU - Warltier, David C.
PY - 2010/1
Y1 - 2010/1
N2 - Background: The role of endothelial nitric oxide synthase (eNOS) in isoflurane postconditioning (IsoPC)-elicited cardioprotection is poorly understood. The authors addressed this issue using eNOS mice. Methods: In vivo or Langendorff-perfused mouse hearts underwent 30 min of ischemia followed by 2 h of reperfusion in the presence and absence of postconditioning produced with isoflurane 5 min before and 3 min after reperfusion. Ca-induced mitochondrial permeability transition (MPT) pore opening was assessed in isolated mitochondria. Echocardiography was used to evaluate ventricular function. Results: Postconditioning with 0.5, 1.0, and 1.5 minimum alveolar concentrations of isoflurane decreased infarct size from 56 ± 10% (n = 10) in control to 48 ± 10%, 41 ± 8% (n = 8, P < 0.05), and 38 ± 10% (n = 8, P < 0.05), respectively, and improved cardiac function in wild-type mice. Improvement in cardiac function by IsoPC was blocked by N-nitro-l-arginine methyl ester (a nonselective nitric oxide synthase inhibitor) administered either before ischemia or at the onset of reperfusion. Mitochondria isolated from postconditioned hearts required significantly higher in vitro Ca loading than did controls (78 ± 29 μm vs. 40 ± 25 μm CaCl2 per milligram of protein, n = 10, P < 0.05) to open the MPT pore. Hearts from eNOS mice displayed no marked differences in infarct size, cardiac function, and sensitivity of MPT pore to Ca, compared with wild-type hearts. However, IsoPC failed to alter infarct size, cardiac function, or the amount of Ca necessary to open the MPT pore in mitochondria isolated from the eNOS hearts compared with control hearts. Conclusions: IsoPC protects mouse hearts from reperfusion injury by preventing MPT pore opening in an eNOS-dependent manner. Nitric oxide functions as both a trigger and a mediator of cardioprotection produced by IsoPC.
AB - Background: The role of endothelial nitric oxide synthase (eNOS) in isoflurane postconditioning (IsoPC)-elicited cardioprotection is poorly understood. The authors addressed this issue using eNOS mice. Methods: In vivo or Langendorff-perfused mouse hearts underwent 30 min of ischemia followed by 2 h of reperfusion in the presence and absence of postconditioning produced with isoflurane 5 min before and 3 min after reperfusion. Ca-induced mitochondrial permeability transition (MPT) pore opening was assessed in isolated mitochondria. Echocardiography was used to evaluate ventricular function. Results: Postconditioning with 0.5, 1.0, and 1.5 minimum alveolar concentrations of isoflurane decreased infarct size from 56 ± 10% (n = 10) in control to 48 ± 10%, 41 ± 8% (n = 8, P < 0.05), and 38 ± 10% (n = 8, P < 0.05), respectively, and improved cardiac function in wild-type mice. Improvement in cardiac function by IsoPC was blocked by N-nitro-l-arginine methyl ester (a nonselective nitric oxide synthase inhibitor) administered either before ischemia or at the onset of reperfusion. Mitochondria isolated from postconditioned hearts required significantly higher in vitro Ca loading than did controls (78 ± 29 μm vs. 40 ± 25 μm CaCl2 per milligram of protein, n = 10, P < 0.05) to open the MPT pore. Hearts from eNOS mice displayed no marked differences in infarct size, cardiac function, and sensitivity of MPT pore to Ca, compared with wild-type hearts. However, IsoPC failed to alter infarct size, cardiac function, or the amount of Ca necessary to open the MPT pore in mitochondria isolated from the eNOS hearts compared with control hearts. Conclusions: IsoPC protects mouse hearts from reperfusion injury by preventing MPT pore opening in an eNOS-dependent manner. Nitric oxide functions as both a trigger and a mediator of cardioprotection produced by IsoPC.
UR - http://www.scopus.com/inward/record.url?scp=74049154710&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74049154710&partnerID=8YFLogxK
U2 - 10.1097/ALN.0b013e3181c4a607
DO - 10.1097/ALN.0b013e3181c4a607
M3 - Article
C2 - 19996950
AN - SCOPUS:74049154710
SN - 0003-3022
VL - 112
SP - 73
EP - 85
JO - Anesthesiology
JF - Anesthesiology
IS - 1
ER -